News & articles
FDA Approves MIMRYLO (Rusfertide), a Hepcidin-Mimetic Peptide for Polycythemia VeraThe FDA approved rusfertide (MIMRYLO) on August 28, 2026 for polycythemia vera patients needing frequent phlebotomy—marking the first hepcidin-mimetic peptide therapy in the United States.
- Solvent Recovery and Waste-Intensity Metrics Enter Peptide Supplier Scorecards
Peptide suppliers face new scorecard metrics on solvent recovery and waste intensity in 2026.
- Focusing on green production, peptide factories help promote sustainable development in the skincare
Focusing on green production: peptide factories and sustainable skincare development.